The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > October 2, 2025
Daily News
October 2, 2025
- AbbVie Aims for Neuroscience Leadership, CSO Says in Tokyo
October 2, 2025
- Think Tanks Urge Unique Value Framework for Regenerative Medicine in 2026 Reform
October 2, 2025
- Kyorin Bags Japan Rights to Hinge Bio’s SLE Med
October 2, 2025
- JCR Out-Licenses Fabry Drug to Oman’s Menagen for MENAT Region
October 2, 2025
- Specialist Urges More COVID Shots for Elderly amid “13th Wave”
October 2, 2025
- Sanofi Sets Sights on 2026 NIP Inclusion of RSV Drug Beyfortus in Japan
October 2, 2025
- Teijin, Australian CDMO Form Alliance for Cell and Gene Therapies in Asia-Pacific
October 2, 2025
- Fuji Pharma Seeks Dysmenorrhea Use for Nextstellis in Thailand
October 2, 2025
- Chugai’s PiaSky Now Available in Taiwan for PNH
October 2, 2025
- JETRO Launches Japan Entry Program for Regenerative Medicine Startups
October 2, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…